Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 5Phase 1 3Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Colorectal Neoplasms 131Colonic Neoplasms 72Rectal Neoplasms 61Breast Neoplasms 61Stomach Neoplasms 37Pancreatic Neoplasms 30Squamous Cell Carcinoma of Head and Neck 27Esophageal Neoplasms 24Head and Neck Neoplasms 23Neoplasm Metastasis 22Esophageal Squamous Cell Carcinoma 16Carcinoma, Hepatocellular 16Adenocarcinoma Of Esophagus 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Neoplasms 11Nasopharyngeal Carcinoma 11Adenocarcinoma 7Urinary Bladder Neoplasms 5Keratosis, Actinic 5Cholangiocarcinoma 5Anus Neoplasms 5Intestinal Neoplasms 4Inflammatory Breast Neoplasms 4Hepatoblastoma 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Biliary Tract Neoplasms 4Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3HIV Infections 3

Interventions

Gemcitabine 28Cisplatin 26Mitomycin 18BCG Vaccine 12pembrolizumab 9Paclitaxel 8Doxorubicin 7Docetaxel 75-aminolevulinic acid hexyl ester 7apaziquone 6Carboplatin 6vinflunine 5enfortumab vedotin 5atezolizumab 5Vinblastine 5Radiotherapy 5Methotrexate 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cystectomy 5durvalumab 4Surgical Procedures, Operative 4Nivolumab 4Transurethral Resection of Bladder 3Specimen Handling 3Selenium 3Radiation 3Filgrastim 3Cystoscopy 3BCG Connaught 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Urinary Bladder Neoplasms × Fluorouracil × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT03775265 2026-05-04

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
475 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07097142 2026-05-04

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NRG Oncology

Phase 3 Recruiting
486 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04241185 2026-05-01

MK-3475-992

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
520 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00024349 2013-12-18

Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Completed
350 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡